Cybin (HELP) Share-based Compensation (2020 - 2025)
Cybin (HELP) reported Share-based Compensation of $543.45 for Q2 2025, down 74.4% on a YoY basis from $2123.2 in Q2 2024, and down 99.96% quarter-over-quarter from $1.5 million in Q1 2025.
Cybin (HELP) Share-based Compensation (2020 - 2025) Analysis & Trends
Cybin has reported Share-based Compensation for 6 years, with the latest figure at $543.45 in Q2 2025.
- For the quarter ending Q2 2025, Share-based Compensation fell 74.4% year-over-year to $543.45; the trailing twelve-month figure through Jun 2025 stood at $26.0 million (up 128.79% YoY), and the FY2025 full-year result was $30.8 million, up 199.25% from the prior year.
- Share-based Compensation for Q2 2025 stood at $543.45, down from $1.5 million in the prior quarter.
- The five-year high for Share-based Compensation was $24.5 million in Q3 2024, with the low at $543.45 in Q2 2025.
- Historically, Share-based Compensation has averaged $3.7 million across 5 years, with a median of $1.1 million in 2023.
- The largest YoY upside for Share-based Compensation was 2225.56% in 2024 against a maximum downside of 99.78% in 2024.
- Cybin's Share-based Compensation stood at $3.5 million in 2021, then sank by 79.62% to $720495.5 in 2022, then plunged by 98.99% to $7292.5 in 2023, then plunged by 67.19% to $2392.4 in 2024, then slumped by 77.28% to $543.45 in 2025.
- The last three Share-based Compensation figures came in at $543.45 (Q2 2025), $1.5 million (Q1 2025), and $2392.4 (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 26.47 Mn |
| 10 | Cybin | 75.42 Mn | 75.42 Mn | - | 543.45 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 543.45 |
| Jun 30, 2025 | 543.45 |
| Mar 31, 2025 | 1.46 Mn |
| Mar 31, 2025 | 1.46 Mn |
| Dec 31, 2024 | 2,392.37 |
| Dec 31, 2024 | 2,392.37 |
| Sep 30, 2024 | 24.53 Mn |
| Sep 30, 2024 | 24.53 Mn |
| Jun 30, 2024 | 2,123.23 |
| Jun 30, 2024 | 2,123.23 |
| Mar 31, 2024 | 10.30 Mn |
| Mar 31, 2024 | 10.30 Mn |
| Dec 31, 2023 | 7,292.47 |
| Dec 31, 2023 | 7,292.47 |
| Sep 30, 2023 | 1.05 Mn |
| Sep 30, 2023 | 1.05 Mn |
| Jun 30, 2023 | 949,176.89 |
| Jun 30, 2023 | 949,176.89 |
| Dec 31, 2022 | 720,495.48 |
| Dec 31, 2022 | 720,495.48 |